drugset / Trial / NCT05837299
A Study of IMC008 for Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
An open label, multi-center, dose-escalating study to evaluate the safety and preliminary efficacy of IMC008 in CLDN18.2 positive advanced solid tumors.
Timeline
- Start
- 2023-04-02
- Primary completion
- 2025-12-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMC008 | Cell therapy | — | — |